Editas Medicine Financial Statements (EDIT)
|
|
|
|
Report date
|
|
|
24.02.2022 |
22.02.2023 |
28.02.2024 |
05.03.2025 |
09.03.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
25.5 |
19.7 |
78.1 |
32.3 |
40.5 |
|
38.7 |
|
Operating Income, bln rub |
|
|
-193.1 |
-226.0 |
-169.2 |
-251.2 |
-99.3 |
|
-115.1 |
|
EBITDA, bln rub |
? |
|
-188.1 |
-219.6 |
-163.1 |
-233.1 |
-148.6 |
|
-101.2 |
|
Net profit, bln rub |
? |
|
-192.5 |
-220.4 |
-153.2 |
-237.1 |
-160.1 |
|
-109.0 |
|
|
OCF, bln rub |
? |
|
-163.8 |
-177.3 |
-132.2 |
-210.3 |
-165.2 |
|
-140.5 |
|
CAPEX, bln rub |
? |
|
7.98 |
4.12 |
4.72 |
8.83 |
0.607 |
|
0.585 |
|
FCF, bln rub |
? |
|
-171.8 |
-181.5 |
-136.9 |
-219.1 |
-165.8 |
|
-141.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
213.6 |
239.3 |
241.2 |
283.5 |
139.9 |
|
153.3 |
|
Cost of production, bln rub |
|
|
5.05 |
6.34 |
6.06 |
0.000 |
0.000 |
|
0.483 |
|
R&D, bln rub |
|
|
142.5 |
175.0 |
177.7 |
199.2 |
90.0 |
|
66.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
6.17 |
|
12.1 |
|
|
Assets, bln rub |
|
|
677.5 |
514.3 |
499.2 |
341.6 |
186.5 |
|
149.3 |
|
Net Assets, bln rub |
? |
|
553.6 |
360.7 |
349.1 |
134.3 |
27.3 |
|
4.41 |
|
Debt, bln rub |
|
|
26.4 |
43.9 |
48.5 |
35.0 |
76.7 |
|
72.0 |
|
Cash, bln rub |
|
|
499.8 |
344.3 |
323.1 |
269.9 |
146.6 |
|
123.6 |
|
Net debt, bln rub |
|
|
-473.5 |
-300.3 |
-274.6 |
-234.9 |
-69.9 |
|
-51.7 |
|
|
Ordinary share price, rub |
|
|
26.6 |
|
|
1.27 |
2.05 |
|
3.07 |
|
Number of ordinary shares, mln |
|
|
67.6 |
68.7 |
76.0 |
82.3 |
88.7 |
|
97.9 |
|
|
Market cap, bln rub |
|
|
1 795 |
0 |
0 |
105 |
182 |
|
300 |
|
EV, bln rub |
? |
|
1 322 |
-300 |
-275 |
-130 |
112 |
|
248 |
|
Book value, bln rub |
|
|
554 |
361 |
349 |
134 |
27 |
|
4 |
|
|
EPS, rub |
? |
|
-2.85 |
-3.21 |
-2.02 |
-2.88 |
-1.80 |
|
-1.11 |
|
FCF/share, rub |
|
|
-2.54 |
-2.64 |
-1.80 |
-2.66 |
-1.87 |
|
-1.44 |
|
BV/share, rub |
|
|
8.19 |
5.25 |
4.60 |
1.63 |
0.31 |
|
0.05 |
|
|
EBITDA margin, % |
? |
|
-736.3% |
-1 114% |
-208.8% |
-721.4% |
-366.8% |
|
-261.5% |
|
Net margin, % |
? |
|
-753.6% |
-1 118% |
-196.1% |
-733.7% |
-395.0% |
|
-281.6% |
|
FCF yield, % |
? |
|
-9.57% |
|
|
-209.5% |
-91.2% |
|
-47.0% |
|
ROE, % |
? |
|
-34.8% |
-61.1% |
-43.9% |
-176.6% |
-586.6% |
|
-2 472% |
|
ROA, % |
? |
|
-28.4% |
-42.9% |
-30.7% |
-69.4% |
-85.8% |
|
-73.0% |
|
|
P/E |
? |
|
-9.33 |
0.00 |
0.00 |
-0.44 |
-1.14 |
|
-2.75 |
|
P/FCF |
|
|
-10.5 |
0.00 |
0.00 |
-0.48 |
-1.10 |
|
-2.13 |
|
P/S |
? |
|
70.3 |
0.00 |
0.00 |
3.24 |
4.49 |
|
7.75 |
|
P/BV |
? |
|
3.24 |
0.00 |
0.00 |
0.78 |
6.67 |
|
68.1 |
|
EV/EBITDA |
? |
|
-7.03 |
1.37 |
1.68 |
0.56 |
-0.75 |
|
-2.45 |
|
Debt/EBITDA |
|
|
2.52 |
1.37 |
1.68 |
1.01 |
0.47 |
|
0.51 |
|
|
R&D/CAPEX, % |
|
|
1 786% |
4 249% |
3 765% |
2 258% |
14 819% |
|
11 315% |
|
|
CAPEX/Revenue, % |
|
|
31.2% |
20.9% |
6.04% |
27.3% |
1.50% |
|
1.51% |
|
| Editas Medicine shareholders |
